by Jazzmin Huber | Aug 3, 2023 | Clinical Trials, Research
We were delighted to award Dr Tanya Heim a travel grant to present her work at FACTOR. Find out more about her work and FACTOR in her guest blog post. I have been a biomedical research scientist for over a decade. I have not always studied cancer, but I have always...
by Jazzmin Huber | Jul 20, 2023 | Clinical Trials, Research
Making it better for young people with Osteosarcoma is the mission of MIB Agents. Every year they bring together patients, families, doctors and researchers to drive forward research into bone cancer. This June the conference, called FACTOR, took place in Atlanta and...
by Jazzmin Huber | Jul 6, 2023 | Uncategorized
We were delighted to award Dr Wolfgang Paster a travel grant to present his work at the 20th Annual Meeting of Cancer Immunotherapy (CIMT) earlier this year. Find out more about his work and the CIMT meeting in his guest blog post. My name is Dr Wolfgang Paster, and I...
by Jazzmin Huber | Jun 23, 2023 | Clinical Trials, Research
Every year cancer experts from across the world come together for The American Society of Clinical Oncology Annual Meeting (ASCO). The aim of ASCO is to share knowledge and provide updates on cancer research. By working together we hope to develop new cancer...
by Jazzmin Huber | Apr 6, 2023 | Research
Researchers at the University of East Anglia have developed a new drug that works against bone cancer including osteosarcoma (OS). The drug, called CADD522, has shown promising results in the laboratory. It will now undergo formal toxicology assessment before...
